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OBJECTIVE — To determine the effects of the Dietary Approaches to Stop Hypertension
(DASH) eating pattern on cardiometabolic risks in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — A randomized crossover clinical trial was
undertaken in 31 type 2 diabetic patients. For 8 weeks, participants were randomly assigned to
a control diet or the DASH eating pattern.
RESULTS — After following the DASH eating pattern, body weight (P  0.007) and waist
circumference (P  0.002) reduced signiﬁcantly. Fasting blood glucose levels and A1C de-
creased after adoption of the DASH diet (29.4  6.3 mg/dl; P  0.04 and 1.7  0.1%; P 
0.04, respectively). After the DASH diet, the mean change for HDL cholesterol levels was higher
(4.3  0.9 mg/dl; P  0.001) and LDL cholesterol was reduced (17.2  3.5 mg/dl; P  0.02).
Additionally, DASH had beneﬁcial effects on systolic (13.6  3.5 vs. 3.1  2.7 mmHg; P 
0.02) and diastolic blood pressure (9.5  2.6 vs. 0.7  3.3 mmHg; P  0.04).
CONCLUSIONS — Among diabetic patients, the DASH diet had beneﬁcial effects on car-
diometabolic risks.
Diabetes Care 34:55–57, 2011
C
ardiovascular complications are
the most frequent problem among
type 2 diabetic patients (1). There-
fore, a therapeutic approach that can
control cardiometabolic risks might
have beneﬁcial effects for diabetic pa-
tients (2).
Although the Dietary Approaches to
Stop Hypertension (DASH) diet was origi-
nally developed to prevent or treat high
blood pressure (2), it is now recommended
as an ideal eating pattern for all adults (3).
Effects of the DASH eating pattern in pa-
tients with metabolic syndrome (4) and hy-
pertension (5,6) and other populations
(7,8) can be generalized to individuals with
diabetes.
Therefore, we assessed how the
DASH eating pattern affects cardiometa-
bolic risks in type 2 diabetic patients.
RESEARCH DESIGN AND
METHODS— We enrolled 44 pa-
tients diagnosed with type 2 diabetes at
the Shaheed Motahari Hospital of
Fooladshahr, Isfahan, during 2009. On
the basis of the sample size formula sug-
gested for crossover trials (9) n[(Z1/2 
Z1)
2 S
2]/2
2, we determined that 21
patientswereneededforadequatepower.
A diagnosis of type 2 diabetes was
conﬁrmed if a patient either had a fast-
ing plasma glucose 126 mg/dl or was
taking oral glucose lowering agents or
insulin(10).Exclusioncriteriaincluded
any secondary cause of hyperglycemia,
use of estrogen therapy, untreated hy-
pothyroidism, smoking, and kidney or
liverdiseases.Cardiovascularriskssuch
as fasting blood glucose, A1C, weight,
waist circumference, and lipid pro-
ﬁles were the primary outcomes. All
participants provided informed written
consent. This study was approved by the
research council and ethics committee of
the Isfahan University of Medical Sciences
(registered in http://www.clinicaltrials.gov;
ID number NCT01049321).
Study procedures
We used a randomized crossover de-
sign. After a run-in period of 3 weeks,
patients were randomly assigned to a
control diet or a DASH diet for 8 weeks.
This was followed by a wash-out period
of 4 weeks. The project dietitian en-
rolled participants and randomly allo-
cated them to groups using random
sequencinggeneratedinSPSSattheend
of the run-in period. Because this was a
dietary intervention, patients were not
blinded.
Diets
We prescribed two diets for each pa-
tient: the control diet and the DASH
diet. The control diet included a macro-
nutrient composition of 50–60% car-
bohydrates, 15–20% protein, 	30%
totalfat,and	5%ofcaloricintakefrom
simple sugars (11). This composition
was more similar to the Iranian dietary
pattern and dietary habits. The DASH
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grains, low-fat dairy products, and low
insaturatedfat,totalfat,cholesterol,re-
ﬁned grains, and sweets. The amount of
sodium intake was 2,400 mg per day
(3). Patient adherence was assessed in
terms of attendance at monthly visits
and through analysis of the 3-day food
diaries.
Measurements
All measurements were taken according
to standard protocols. The laboratory
staff was blinded to the treatment
status.
Statistical analysis
We used general linear models (paired
Student t tests) to globally compare
means of the all variables at the end of the
two different diet periods and the mean
change for each variable in the two
groups. Statistical analyses were per-
formed using SPSS for Windows version
13.0 (SPSS, Chicago, IL).
RESULTS— Ofthe44participants,31
type 2 diabetic patients (13 male and 18
female) completed the entire crossover
study (one patient was diagnosed with
cancer and one with anemia, and eleven
patients did not follow the study
protocol).
Analysis of the 3-day diet self-report
showed that calorie intake of two the
groups was not signiﬁcantly different
(2,165  29 vs. 2,189  35 Kcal/day in
the control and DASH diets, respectively;
P  0.62). The results were the same re-
garding the actual protein intake (15 vs.
16%) and total fat intake (28 vs. 29%) as
wellasthepercentageofthecarbohydrate
intake (57 vs. 55%) in the control and
DASH diet groups, respectively. These
two diets were different in sodium con-
tent (2,310 vs. 2,996 mg/day in the con-
trol and DASH diets, respectively). The
DASH diet had higher amount of calcium
(1,299 vs. 912 mg/day), potassium
(4,399vs.3,219mg/day)andﬁber(30vs.
26g/day).IntheDASHeatingpatternver-
sus the control diet, the number of serv-
ings of fruit (5 vs. 3), vegetables (6.8 vs.
4), dairy (3 vs. 2), and whole grains (4.5
vs. 2.5) was higher.
Effects of the two diets on cardiom-
etabolic risks are shown in Table 1, indi-
cating a signiﬁcant reduction in most risk
factors from the DASH diet.
CONCLUSIONS — We found that
the DASH-eating pattern had beneﬁcial
effects on type 2 diabetic patients’ cardio-
metabolic parameters.
The prescribed caloric intake of both
dietswasthesame,butthecaloriedensity
of food in the DASH diet was lower than
that in the control diet. A long-term–
weight-loss trial over 18 months also in-
dicated beneﬁcial effects of using low-
calorie–dense diets for weight loss (12).
Furthermore, the dairy content, which
mightberelatedtoweightreduction(13),
was higher in the DASH diet was higher
than the control diet.
The DASH eating pattern also had a
more beneﬁcial impact on the patient’s
glycemic control. More ﬁber, phytoestro-
Table 1—Means of the cardiometabolic variables among type 2 diabetic patients after con-
sumption of the DASH or control diet
Control diet* DASH diet† P‡
n 31 31
Weight (kg)
Baseline 75.0  1.7 73.4  1.8 0.001
End of trial 72.9  1.8 68.4  1.7 0.001
Change 2.0  0.3 5.0  0.9 0.006
Waist circumference (cm)
Baseline 104.6  1.9 103.4  2.0 0.01
End of trial 102.7  2.0 96.6  1.9 0.001
Change 1.9  0.4 6.7  1.2 0.002
SBP (mmHg)
Baseline 137.4  2.8 134.5  3.8 0.39
End of trial 134.2  3.1 120.8  3.2 0.001
Change 3.1  2.7 13.6  3.5 0.02
DBP (mmHg)
Baseline 81.9  2.2 81.8  1.7 0.95
End of trial 81.2  2.9 72.2  2.7 0.01
Change 0.7  3.3 9.5  2.6 0.04
FBG (mg/dl)
Baseline 171.8  10.9 160.9  10.1 0.73
End of trial 159.0  8.3 131.5  7.3 0.003
Change 12.8  6.7 29.4  6.3 0.04
A1C (%)
Baseline 7.9  1.9 7.7  1.9 0.19
End of trial 7.4  1.7 6.1  0.5 0.05
Change 0.5  0.02 1.7  0.1 0.04
TG (mg/dl)
Baseline 189.7  19.3 170.7  12.4 0.17
End of trial 178.7  18.4 185.1  13.8 0.53
Change 10.9  6.8 14.4  10.7 0.79
HDL-C (mg/dl)
Baseline 41.2  1.0 41.2  1.0 0.97
End of trial 42.5  1.0 45.6  1.1 0.001
Change 1.3  0.7 4.3  0.9 0.001
LDL-C (mg/dl)
Baseline 114.7  3.5 118.7  3.6 0.23
End of trial 111.9  4.1 101.5  3.1 0.02
Change 2.7  4.8 17.2  3.5 0.02
Total cholesterol (mg/dl)
Baseline 213.3  6.0 214.9  5.7 0.80
End of trial 205.0  6.6 192.7  4.6 0.03
Change 8.3  6.3 22.1  5.7 0.11
Data are means  SE. *The control diet was a designed to control diabetes. The general recommenda-
tionformacronutrientcompositionofthedietwas50–60%carbohydrates;15–20%proteinand	30%
total fat. The amount of simple sugar was less than 5% of calorie intake. †The DASH diet was rich in
fruits, vegetables, whole grains, and low-fat dairy products, and low in saturated fat, total fat, choles-
terol, reﬁned grains, and sweets. The amount of sodium intake was 2,400 mg per day. ‡P values are for
comparisons between the two diet periods (general linear model). DBP, diastolic blood pressure; FBG,
fasting blood glucose; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; SBP, systolic blood pressure;
TG, triglyceride.
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fruit and vegetable consumption, along
with more weight reduction might be re-
sponsible for these effects (4).
The present study suggests the DASH
diet plan could reduce LDL and increase
HDL cholesterol. Our previous research
onpatientswithmetabolicsyndromealso
indicates a beneﬁcial effect of this type of
diet on lipid proﬁles (4). There was no
difference in the serum triglyceride levels
when we compared the effects of the two
diets. However, DASH was compared
withthecontroldiet,whichalsohadben-
eﬁcial effects on lowering the serum tri-
glyceride level.
Higher intake of legumes such as soy
in the DASH diet might also be responsi-
ble for its beneﬁcial effects on metabolic
parameters (14). The kind of fat con-
sumption in different diets is also impor-
tant. Consuming higher amounts of
nonhydrogenated vegetable oil with the
DASH diet might be related to its more
favorable effects.
Becausenonadherentparticipantsdid
not participate in all phases of the study,
we could not use intention-to-treat anal-
ysis. Dietary intake in the present study
wasself-reported,andpatientsweregiven
recommendations to follow a particular
diet (rather than receiving prepared
foods), likely resulting in possible imper-
fect adherence to the diets. The Omni-
Heart (Optimal Macro-nutrient Intake
Heart) study (15) has expanded the ma-
cronutrient variability of the DASH di-
etary pattern, which will be interesting to
explore in future studies.
TheDASHeatingpatternmayplayan
important role in managing cardiometa-
bolicrisksamongtype2diabeticpatients.
Longer-term studies are needed to assess
the sustainability of these effects.
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